CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled / 40 target
Drug / intervention
ROSE-010 99 mcg +2 moredrug
Likely dose
ROSE-010 99 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06621017
NCT06621017Phase 2CompletedHigh Momentum (1.9/mo)Completion was 16mo ago
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Daily Administrations of the GLP-1 Analogue ROSE-010 on Appetite and Food Intake in Overweight and Obese Subjects

Rose Pharma Inc·interventional·Posted Oct 1, 2024·Updated Jun 1, 2026

In Brief

A Phase 2 clinical trial evaluating ROSE-010 99 mcg, Placebo, and 1 other intervention for Obesity; Overweight. Completed, enrolled 40 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity. The secondary objectives of this study are the following: * To assess the efficacy of ROSE-010 on hunger; * To assess the efficacy of ROSE-010 on satiety; * To assess the efficacy of ROSE-010 on prospective consumption; * To assess the efficacy of ROSE-010 on desire to eat; * To assess the efficacy of ROSE-010 on palatability; * To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and * To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity; Overweight
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedOct 1, 2024
Enrollment StartSep 26, 2024
Primary CompletionFeb 27, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.8 years ago

Arms & Interventions

Placeboplacebo_comparator

Saline solution

Drug: Placebo
ROSE-010 99 mcgexperimental

ROSE-010 solution, 99 mcg, 0.5 ml

Drug: ROSE-010 99 mcg
ROSE-010 150 mcgexperimental

ROSE-010 solution, 150 mcg, 0.5 ml

Drug: ROSE-010 150 mcg

Interventions

ROSE-010 99 mcgdrug

Sub-cutaneous injection of ROSE-010 solution

Placebodrug

Sub-cutaneous injection of saline solution

ROSE-010 150 mcgdrug

Sub-cutaneous injection of ROSE-010 solution